Published in Arthritis Res Ther on September 15, 2005
An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res (2007) 1.57
Heterotopic ossification after hip arthroscopy. J Hip Preserv Surg (2015) 0.88
Indirect role of alpha2-adrenoreceptors in anti-ulcer effect mechanism of nimesulide in rats. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.88
Interaction of the human prostacyclin receptor with Rab11: characterization of a novel Rab11 binding domain within alpha-helix 8 that is regulated by palmitoylation. J Biol Chem (2010) 0.87
NSAIDs Alter Phosphorylated Forms of AQP2 in the Inner Medullary Tip. PLoS One (2015) 0.81
Cost-effectiveness analysis for joint pain treatment in patients with osteoarthritis treated at the Instituto Mexicano del Seguro Social (IMSS): Comparison of nonsteroidal anti-inflammatory drugs (NSAIDs) vs. cyclooxygenase-2 selective inhibitors. Cost Eff Resour Alloc (2008) 0.81
What is the future of stroke prevention?: debate: polypill versus personalized risk factor modification. Stroke (2010) 0.80
Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. Arthritis Res Ther (2005) 0.80
Inhibition of nuclear factor kappaB activation and cyclooxygenase-2 expression by aqueous extracts of Hispanic medicinal herbs. J Med Food (2010) 0.79
Drug Targets for Cardiovascular-Safe Anti-Inflammatory: In Silico Rational Drug Studies. PLoS One (2016) 0.75
Concern Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med (2000) 29.03
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med (1989) 13.83
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet (2004) 9.88
Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med (2005) 6.32
Effect of ibuprofen on cardioprotective effect of aspirin. Lancet (2003) 6.07
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med (2001) 5.96
Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet (2002) 5.17
Coxibs and cardiovascular disease. N Engl J Med (2004) 4.42
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology (1999) 4.13
Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1993) 4.05
Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology (1989) 3.60
Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med (1994) 2.74
Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology (2000) 2.63
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation (2001) 2.55
Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol (2005) 2.50
COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 2.49
Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med (2002) 2.45
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med (2003) 2.18
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology (2003) 2.00
Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation (2003) 2.00
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med (2005) 1.72
Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med (2005) 1.56
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J (1991) 1.54
Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med (2005) 1.49
Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol (1991) 1.48
Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol (2003) 1.37
Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. BMJ (2004) 1.36
Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (1997) 1.28
Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther (2001) 1.26
Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med (2005) 1.24
The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum (2004) 1.19
The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol (2003) 1.17
Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am (1996) 1.14
Cardiovascular disease risk reduction in the Behavioral Risk Factor Surveillance System. Am J Prev Med (2004) 1.09
Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. Pain (2004) 1.01
Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci (1998) 0.98
Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis. Aliment Pharmacol Ther (2004) 0.92
Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther (1985) 0.84
Over-the-counter pain reliever and aspirin use within a sample of long-term cyclooxygenase 2 users. Arch Intern Med (2004) 0.78
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. J Rheumatol (2009) 1.81
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med (2005) 1.72
Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol (2005) 1.70
Fibromyalgia syndrome. J Rheumatol (2005) 1.49
Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol (2011) 1.49
Patient-reported outcomes in chronic gout: a report from OMERACT 10. J Rheumatol (2011) 1.10
Double-blind placebo-controlled trial of static magnets for the treatment of osteoarthritis of the knee: results of a pilot study. Altern Ther Health Med (2004) 1.02
Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol (2009) 0.99
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology? J Rheumatol (2011) 0.92
Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J Rheumatol Suppl (2008) 0.91
Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol (2011) 0.91
Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: outcomes of importance for patients with PMR. J Rheumatol (2014) 0.90
GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial. Am J Gastroenterol (2013) 0.88
Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol (2011) 0.88
Tophus measurement as an outcome measure for clinical trials of chronic gout: progress and research priorities. J Rheumatol (2011) 0.87
The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. Cancer (2004) 0.86
A first step to assess harm and benefit in clinical trials in one scale. J Clin Epidemiol (2009) 0.85
Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus. Arthritis Rheum (2004) 0.84
Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk. Pain Pract (2013) 0.84
Nonsteroidal anti-inflammatory drugs and their risk: a story still in development. Arthritis Res Ther (2013) 0.82
Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. Pain (2016) 0.82
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain (2016) 0.81
The use of rheumatoid arthritis health-related quality of life patient questionnaires in clinical practice: lessons learned. Arthritis Rheum (2003) 0.81
Meta-analysis of assay sensitivity and study features in clinical trials of pharmacologic treatments for osteoarthritis pain. Arthritis Rheumatol (2014) 0.81
Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout. J Rheumatol (2014) 0.79
Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group. J Rheumatol (2006) 0.79
Advice from professional societies: appropriate use of NSAIDs. Pain Med (2013) 0.79
Hyperbole, innuendo, and fact: the strange case of COX-2 selective inhibitors. J Rheumatol (2006) 0.79
Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk. Arthritis Res Ther (2006) 0.79
AJC Editor's consensus: Selective and nonselective nonsteroidal anti-inflammatory drugs and cardiovascular risk. Am J Cardiol (2010) 0.78
Development of a bedside pain assessment kit for the classification of patients with osteoarthritis. Rheumatol Int (2014) 0.77
Further qualification of a therapeutic responder index for patients with chronic low back pain. J Rheumatol (2010) 0.77
Chronic pain and fibromyalgia: the regulatory perspective. Best Pract Res Clin Rheumatol (2003) 0.77
Updating the OMERACT filter: implications for imaging and soluble biomarkers. J Rheumatol (2014) 0.77
OMERACT endorsement of measures of outcome for studies of acute gout. J Rheumatol (2013) 0.76
OMERACT 10--International Consensus Conference on Outcome Measures in Rheumatology Clinical Trials. J Rheumatol (2011) 0.75
Outcome measures in rheumatoid arthritis: the OMERACT process. Expert Rev Clin Immunol (2007) 0.75
OMERACT 9 - 9th International Consensus Conference on outcome measures in rheumatology clinical trials. J Rheumatol (2009) 0.75
Efficacy and safety of CH-1504, a metabolically stable antifolate, in patients with active rheumatoid arthritis: results of a phase II multicenter randomized study. J Rheumatol (2011) 0.75
Analysis of aspirin-associated risks in healthy individuals. Ann Pharmacother (2004) 0.75